Dr. Brian G.M. Durie (1942-2025) was the co-founder of the IMF. He was a Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels.
This webpage has been archived. The information provided here may be outdated. Looking for more updated and relevant content? Search the International Myeloma Foundation website for the latest and most relevant information.
October 1, 2020
We had all hoped COVID-19 would be behind us by now. However, the increasing number of cases in many parts of the U.S. and many countries globally has prompted serious concerns about what is to come. We clearly need to stay vigilant and continue to adapt to the constraints of the new COVID-19 world.
Although it is perhaps a little unfair to compare outcomes and strategies in a small country like Iceland with many much larger nations, there are still important scientific lessons to be gleaned. In mid-September, there was a sudden spike in the number of COVID -19 cases in a country that had previously had close to zero cases. So, what happened?
Scientists in Houston just released the results of a study in which they checked for mutations in over 5,000 COVID-19 cases. The main finding supports earlier studies indicating that a dominant mutation (D614G), which first emerged in Italy, was responsible (99.9%) for a second wave of infections in Houston this summer. This strain led to many more infections in younger individuals.
Researchers have found that this D614G-mutated COVID-19 virus strain spreads more easily and produces higher virus loads, potentially leading to more super-spreader events. The fact that many additional mutations were also found leads to a concern that new strains will repeatedly and sequentially emerge, evading the body’s immune control and potentially frustrating the ability to have an effective vaccine. It could be that, as with the flu, new vaccines will be required each year.
Operation Warp Speed, an initiative to accelerate development of a COVID-19 vaccine, is a huge, highly structured organization funded with $10 billion and involving both civilian and military personnel. One can only marvel at the potential and hope that there will indeed be success in developing, manufacturing and distributing an effective and safe vaccine in a greatly accelerated timeline.
A very comprehensive review of all SARS-CoV-2 (COVID-19) vaccines in development was recently published, but many questions have been raised. One issue is that not enough older individuals have been entered into vaccine trials. In a recent study, the median age of participants was 40. A small study of COVID-19 vaccination in older adults is encouraging, however, especially at a higher dose. In addition, concern has been raised that vaccines will not work well in obese individuals, one of the key higher risk groups. Obviously, there is an additional concern that vaccines will not work well in those with compromised immune systems, such myeloma patients.
Many questions remain to be answered as we await developments in the coming weeks and months.
As I have noted in previous blogs, many animals, from goats to lions, have rapidly adapted to the quieter environment during the COVID-19 pandemic. In San Francisco, researchers have observed that noise in the city has dropped a lot (by seven decibels) due to less traffic and human activity. The male sparrows have reacted by lowering the volume of their songs by four decibels (softer, but still loud enough because of less background noise) and using a broader bandwidth, which is attractive to female sparrows.
This ability to rapidly react in the face of a massive environmental change is truly heartwarming as it reflects a true resilience in the natural world.
As we face an autumn of uncertainty, it is wonderful to have a new publication from Cigna and the Resilience Research Center. What is especially helpful in the report is the detailed discussion of how to build resilience, which I have discussed in several blogs and in a conversation with Sue Dunnett.
The approach developed by the Resilience Research Center team is divided into six steps:
These steps illustrate that resilience is not a passive process, but a quality that can be strengthened with focused effort. If we in the myeloma community work together to strengthen our resilience, we can get through the next phase of the COVID-19 crisis with much more ease and confidence.
Stay safe and be well!
Dr. Brian G.M. Durie (1942-2025) was the co-founder of the IMF. He was a Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels.